What is Zai Lab Limited (ZLAB)?

Zai Lab Limited (ZLAB) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ZLAB?

The current price of ZLAB is $23.04. Prices are updated in real time on Stocks360.

What is ZLAB's price-to-earnings (PE) ratio?

ZLAB's trailing twelve-month PE ratio is -13.30, based on current price and earnings per share data available on Stocks360.

What is ZLAB's market capitalization?

ZLAB's market capitalization is $2,586,613,732.00, placing it in the mid-cap tier.

Zai Lab Limited (ZLAB)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$23.04

Market Cap

$2.59B

PE (TTM)

-13.30

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.83

Day Range

$22.63 – $23.49

52-wk Range

$15.96 – $27.50

Avg Volume

N/A

Volume

704.03K

Zai Lab Limited (ZLAB) is a publicly traded company in the Healthcare sector. Latest price: $23.04. Market cap $2.59B. Trailing PE -13.30. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $25.32 2026-10-28 · $23.04 (-9.00%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.46 vs est. $-0.68

Beat by $0.22

Next Earnings

Nov 5, 2026

EPS estimate $-0.56

Proprietary Signals

Signal snapshot temporarily unavailable.

About Zai Lab Limited

Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline can…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-13.30×
P/S (TTM)	5.82×
P/B	4.27×
P/FCF (TTM)	-19.41×
EV / EBITDA	-10.99×
EV / Sales	5.04×
Earnings Yield	-7.26%
Free Cash Flow Yield	-5.15%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.26B
Revenue (TTM)	$449.20M
Net Income (TTM)	-$189.88M
Free Cash Flow (TTM)	-$149.27M
Net Debt	-$352.95M
Working Capital	$485.45M
Gross Margin	56.47%
Operating Margin	-58.73%
Net Margin	-41.86%
Return on Equity	-27.40%
Return on Invested Capital	-29.28%